Perrigo (PRGO) reported $1.08 billion in revenue for the quarter ended March 2024, representing a year-over-year decline of 8.4%. EPS of $0.29 for the same period compares to $0.45 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $1.09 billion, representing a surprise of -0.91%. The company delivered an EPS surprise of +20.83%, with the consensus EPS estimate being $0.24.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street ex ...

EXHIBIT 99.1 Perrigo Reports First Quarter 2024 Financial Results From Continuing Operations Delivered Adjusted Diluted Earnings Per Share Results Above Projection, Due Primarily to Timing of Infant Formula Shipments; Reaffirm 2024 Financial Outlook Advanced Augmenting and Strengthening of Infant Formula Facilities, Recovery of Manufacturing Volumes Underway Progressed Blueprint to Build One Perrigo; On Target to Deliver Project Energize Goals; Announced Today in a Separate Press Release the Executive Trans ...

Delivered Adjusted Diluted Earnings Per Share Results Above Projection, Due Primarily to Timing of Infant Formula Shipments; Reaffirm 2024 Financial Outlook Advanced Augmenting and Strengthening of Infant Formula Facilities, Recovery of Manufacturing Volumes Underway Progressed Blueprint to Build One Perrigo; On Target to Deliver Project Energize Goals; Announced Today in a Separate Press Release the Executive Transition for the Consumer Self-Care International Business Recently Announced Plan to Divest HR ...

Svend Andersen, EVP and President Consumer Self-Care International (CSCI), to Retire Roberto Khoury, a Global Branded Consumer Health Veteran, Appointed to Lead the Business DUBLIN, May 7, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that Svend Andersen, Executive Vice President and President, Consumer Self-Care International (CSCI), intends to retire from the Company in December of this year. Roberto Khoury, a consumer self-care v ...

The upcoming report from Perrigo (PRGO) is expected to reveal quarterly earnings of $0.24 per share, indicating a decline of 46.7% compared to the year-ago period. Analysts forecast revenues of $1.09 billion, representing a decrease of 7.6% year over year.The current level reflects an upward revision of 0.6% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Prior ...

DUBLIN, May 1, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a quarterly dividend of $0.276 per share, payable on June 18, 2024, to shareholders of record on May 31, 2024. About Perrigo  Perrigo Company plc (NYSE: PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to ...

Perrigo Company plc (PRGO) is scheduled to report first-quarter 2024 results on May 7, before the opening bell. In the last reported quarter, the company posted an earnings surprise of 3.61%.Let’s see how things have shaped up for this announcement.Factors at PlayThe Zacks Consensus Estimate for Perrigo’s total revenues is pegged at around $1.1 billion, while the same for earnings stands at 24 cents per share. Both metrics indicate a decline from the year-ago quarter’s levels.Perrigo reports its results und ...

Proposed Divestment of Branded Prescription Pharma Business Further Supports Perrigo's Strategic Focus on Consumer Self-Care Total Purchase Consideration of up to €275 Million, Consisting of €190 Million in Cash Upfront and up to €85 Million in Potential Earnouts; Based on 2023 Adjusted EBITDA of ~€20M, Total Consideration Would be Accretive to Perrigo's Current Enterprise Value-to-EBITDA Multiple Expected Net Proceeds to be Redeployed for Debt Repayment Expected Impact From this Proposed Divestment was In ...

DUBLIN, April 23, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its first quarter 2024 financial results on Tuesday, May 7th, 2024, and host a conference call beginning at 8:30 A.M. (EDT).The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 888-664-6383, In ...

Core Viewpoint - Perrigo has a strong history of increasing dividends for 20 consecutive years and is positioned to achieve Dividend Champion status, supported by several catalysts in 2024 that could enhance share price and dividend growth [2][26]. Company Overview - Perrigo is a leading provider of over-the-counter medications and therapeutic products, holding a 49% market share in self-care products in the USA, Canada, Europe, and Australia [3][5]. - The healthcare sector is expected to grow long-term due to aging populations and the increasing demand for self-care products [5]. Recent Challenges and Recovery - Perrigo faced difficulties following a proposed acquisition by Mylan, which merged with Upjohn to form Viatris in 2020, impacting its performance over the past decade [5][6]. - The company had to shut down a Wisconsin infant formula plant due to FDA findings, leading to a 25% decline in share price. However, the plant has resumed operations, and revenue from it is expected to contribute positively in 2024 and 2025 [7][9]. Catalysts for Growth - **Manufacturing and Supply Chain Optimization**: The new CEO aims to unlock $150-$200 million in adjusted operating income by 2025 through initiatives like reducing SKU complexity and improving business planning [10][11][14]. - **Good-Better-Best Branding Strategy**: Perrigo plans to introduce a mid-tier product line in the USA, which could improve gross margins by 10-12 percentage points and tap into a growing market segment [19][20]. - **Launch of Opill**: The introduction of Opill, an OTC oral contraceptive, is expected to capture a significant market share, with strong retail support and potential insurance coverage enhancing its adoption [20][21]. - **Upcoming Investor Day**: The company plans to host an investor day to outline strategies for increasing shareholder returns, focusing on dividend growth, deleveraging, and reinvestment in higher-margin product categories [22][25]. Financial Performance and Outlook - Perrigo's gross margin has improved from 36.5% in 2021 to a target of over 40% in the long term, driven by operational efficiencies and pricing strategies [17][18]. - The company is on track to reduce its net leverage ratio to below 3.0X adjusted EBITDA by the end of 2025, contributing to earnings growth [23][25]. Market Position and Future Prospects - The self-care market is projected to grow at a 4% CAGR, with Perrigo positioned to benefit from this trend through its strategic initiatives and product offerings [32][33]. - The company is recognized for its consistent dividend payments, with a current yield of 3.5%, which is attractive compared to other investment options [26][39].